Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 24 Oct 23 EFFECT Notice of effectiveness
- 20 Oct 23 POS AM Prospectus update (post-effective amendment)
- 7 Jun 23 EFFECT Notice of effectiveness
- 31 May 23 POS AM Prospectus update (post-effective amendment)
- 9 Nov 22 424B3 Prospectus supplement
- 9 Nov 22 EFFECT Notice of effectiveness
- 4 Nov 22 F-1/A Registration statement (foreign) (amended)
-
12 Oct 22 F-1 Registration statement (foreign)
AKTX similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Akari Therapeutics, Plc.
London, United Kingdom
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated May 16, 2022, relating to the consolidated financial statements of Akari Therapeutics, Plc. appearing in the Company’s Annual Report on Form 20-F for the year ended December 31, 2021. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/BDO USA, LLP
New York, New York
October 12, 2022